当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Application of Mass Spectrometry Imaging Technology Represents a Breakthrough in Drug Toxicity

Zeki Hosni

Mass spectrometry imaging (MSI) technology has emerged as a transformative tool in drug toxicity assessment, revolutionizing the way pharmaceuticals are evaluated for safety and efficacy. MSI allows for the spatial visualization and simultaneous identification of drug distribution and metabolites within biological tissues, providing unprecedented insights into drug toxicity mechanisms. This article explores the application of MSI technology in drug toxicity assessment and its impact on drug development, early detection of toxic metabolites, personalized medicine, and preclinical safety assessment. By facilitating the understanding of drug-tissue interactions at a cellular level, MSI holds the potential to optimize drug development processes, enhance drug safety, and pave the way for a new era of personalized medicine. This article explores the application of MSI in drug toxicity assessment, highlighting its impact on spatial drug distribution analysis, early detection of toxic metabolites, mechanistic understanding of toxicity, personalized medicine, and preclinical safety assessment. With MSI’s potential to optimize drug development, enhance safety profiles, and advance personalized therapeutic approaches, this technology represents a breakthrough in the pursuit of safer and more effective medications.